Investigational Drug Information for QAW039
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug QAW039?
QAW039 is an investigational drug.
There have been 18 clinical trials for QAW039.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 3rd 2015.
The most common disease conditions in clinical trials are Asthma, Eosinophilia, and Lung Diseases. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are twenty-eight US patents protecting this investigational drug and three hundred and fourteen international patents.
Summary for QAW039
| US Patents | 28 |
| International Patents | 314 |
| US Patent Applications | 113 |
| WIPO Patent Applications | 63 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 3 (2015-12-03) |
| Vendors | 39 |
Recent Clinical Trials for QAW039
| Title | Sponsor | Phase |
|---|---|---|
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. | Novartis Pharmaceuticals | Phase 2 |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia | Novartis Pharmaceuticals | Phase 2 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for QAW039
Top disease conditions for QAW039
Top clinical trial sponsors for QAW039
US Patents for QAW039
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| QAW039 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| QAW039 | See Plans and Pricing | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| QAW039 | See Plans and Pricing | Fused imidazo-piperidine JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for QAW039
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| QAW039 | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| QAW039 | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| QAW039 | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
